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FUTURE OF THE NHS
Is the NHS really safe from international trade
agreements?
Lessons have come from Slovakia
Lucy Reynolds research fellow, London School of Hygiene and Tropical Medicine, UK, Martin McKee
professor of European public health, London School of Hygiene and Tropical Medicine
International trade agreements generally attract little public
scrutiny in the United Kingdom, but while some are
uncontroversial, others are not.1 One, the Transatlantic Trade
and Investment Partnership (TTIP),2 currently being negotiated
between the European Union and United States, even features
in the 2015 UK general election manifestos, with all three main
parties supporting it, albeit with certain reservations, and
upcoming parties such as the Green Party and National Health
Action Party opposing it.3 There are concerns that TTIP, which
will cover over 40% of the world’s economy, would enable
global corporations to over-ride a future UK government seeking
to reverse aspects of NHS privatisation,4 potentially leading to
the replacement of the NHS with a US style market based
system.5
The UK government could opt to remove many aspects of
healthcare from the scope of TTIP, just as the French
government has excluded its cultural sector. Yet the coalition
government has declined to do so, arguing that this is
unnecessary. Prime Minister David Cameron described fears
that the TTIP might damage the NHS as “bogus nonsense” and
an “empty threat.”6Vince Cable, the Liberal Democrat business
secretary, said confidently that there would be no requirement
for a future government to open up more NHS services to
competition or private provision.7 Both refer to the EU
commissioner for trade, who has sought to “correct some of the
misconceptions circulating,”8 asserting that nothing in TTIP
would require a national government to privatise health services
or prevent it from bringing previously privatised services back
into the public sector. Similar reassurances have been given by
other European Commission officials and cited extensively by
UK ministers.
But are they right? Are those expressing concern, including a
wide range of non-governmental organisations such as the UK’s
Faculty of Public Health,9 misinformed or scaremongering? A
tribunal report that has just been released under freedom of
information procedures indicates that there really is a problem.
Bypassing the courts
An appreciation of how trade agreements work helps in
understanding that problem. Because courts often fail to support
companies,10 as with the failure by Japan Tobacco International
to overturn Australia’s ban on branded packaging,11 large
corporations and certain governments initiated an alternative,
the Investor-State Dispute Settlement (ISDS) system.12 This
allows corporations whose profits are threatened, such as by
controls that could reduce the number of cigarettes they sell, to
overturn public health decisions by elected governments. ISDS
bypasses the courts: rulings are given instead by commercial
arbitrators with no requirement to accommodate public policy
objectives. ISDS is a core element of the TTIP.
Why this is important is apparent from an ISDS Tribunal case
arising from the 2008 decision by the Slovakian government to
require health insurers to be not for profit, a principle previously
ruled as lawful under European law by the European Court of
Justice.13 An Austrian bank that owned shares in one of the
previous for-profit companies—thus once removed from any
agreement between the government and the insurers—claimed
compensation for loss of the money that it might have made if
profit making from national health insurance had continued. It
invoked an Austria-Slovakia investment agreement negotiated
in 1990 by the Czechoslovak government and inherited by
Slovakia.14 This treaty allows commercial entities to claim
compensation from public funds through ISDS style “investor
protection” rules against “expropriation” (otherwise known as
renationalisation).
Given the European Commission’s stated confidence that the
TTIP could not be used to circumvent national governments
and courts, it was unsurprising that it argued before the 2010
Slovak trade tribunal set up to hear the case that the tribunal
had no right to do so and that such matters should be settled by
the courts, with the European Court of Justice as final authority.
The trade tribunal rejected this view, ruling that that court had
no monopoly in determining interpretation of European law.
Although the Slovakian government ultimately prevailed,
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because of technical flaws in the case against it, this tribunal
report clarifies several important points.
Firstly, opinions of European Commission officials or
government ministers, Slovak or British, about what an
international trade agreement permits or prevents cannot be
considered definitive.
Secondly, even indirect investors in public services may be able
to penalise governments financially if they seek to roll back the
market in healthcare. They will do this not in the courts, which
apply the law in the public gaze and can accommodate public
policy concerns, but in secret arbitration tribunals.
Thirdly, had Slovakian freedom of information law not permitted
the release of the details of this case wewould never have known
about them.
We still don’t know what is being discussed in the negotiations
on the TTIP. But now we may well draw less comfort from
official reassurances.
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